Xilio Therapeutics, Inc.
Xilio Therapeutics develops masked immuno-oncology therapies designed to activate selectively within the tumor microenvironment.
SCHEDULE 13GNov 16Latest SEC filing
Nov 10Latest story
November 2026
August 2026
Xilio Therapeutics develops masked immuno-oncology therapies designed to activate selectively within the tumor microenvironment.